Pure Bioscience, Inc. PURE
We take great care to ensure that the data presented and summarized in this overview for PURE BIOSCIENCE, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in PURE
Top Purchases
Top Sells
About PURE
PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. The company also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÉRION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California.
Insider Transactions at PURE
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 22
2023
|
Robert F Bartlett CEO and President |
BUY
Open market or private purchase
|
Indirect |
50,000
+50.0%
|
$0
$0.16 P/Share
|
Mar 21
2023
|
Bernard Blotner Director |
BUY
Open market or private purchase
|
Indirect |
10,000
+50.0%
|
$0
$0.13 P/Share
|
Dec 15
2022
|
Tom Y Lee Director |
BUY
Open market or private purchase
|
Direct |
50,000
+0.99%
|
$0
$0.13 P/Share
|
Jul 15
2022
|
David Rendall Director |
BUY
Grant, award, or other acquisition
|
Direct |
325,000
+44.68%
|
$0
$0.15 P/Share
|
Jul 15
2022
|
Tom Y Lee Director |
BUY
Grant, award, or other acquisition
|
Indirect |
21,741,666
+42.54%
|
$0
$0.15 P/Share
|
Jul 15
2022
|
Ivan Chen Director |
BUY
Grant, award, or other acquisition
|
Direct |
300,000
+28.57%
|
$0
$0.15 P/Share
|
Mar 21
2022
|
Tom Y Lee Director |
BUY
Open market or private purchase
|
Direct |
185,000
+3.6%
|
$0
$0.2 P/Share
|
Mar 17
2022
|
Tom Y Lee Director |
BUY
Open market or private purchase
|
Direct |
13,250
+0.28%
|
$0
$0.18 P/Share
|
Mar 16
2022
|
Tom Y Lee Director |
BUY
Open market or private purchase
|
Direct |
21,227
+0.44%
|
$0
$0.18 P/Share
|
Jun 16
2021
|
Tom Y Lee Director |
BUY
Open market or private purchase
|
Direct |
35,998
+0.75%
|
$0
$0.43 P/Share
|
Dec 24
2020
|
Tom Y Lee Director |
BUY
Open market or private purchase
|
Direct |
851
+0.02%
|
$0
$0.65 P/Share
|
Dec 22
2020
|
Tom Y Lee Director |
BUY
Open market or private purchase
|
Direct |
45,299
+0.96%
|
$0
$0.66 P/Share
|
Dec 21
2020
|
Tom Y Lee Director |
BUY
Open market or private purchase
|
Direct |
7,859
+0.17%
|
$0
$0.68 P/Share
|
Dec 17
2020
|
Tom Y Lee Director |
BUY
Open market or private purchase
|
Direct |
4,712
+0.1%
|
$0
$0.65 P/Share
|
Dec 16
2020
|
Tom Y Lee Director |
BUY
Open market or private purchase
|
Direct |
20,000
+0.43%
|
$0
$0.66 P/Share
|